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Dear Editor,
The relatively poor response rates seen with intrave-
nous (IV) antibiotic (AB) therapy and the emergence of 
multidrug-resistant (MDR) microorganisms requires the 
development of new treatment strategies for ventilator-
associated pneumonia (VAP) [1].
We investigated in a prospective double-blind ran-
domized-controlled trial performed in a single center, 
whether empiric adjunctive therapy with inhalation 
tobramycin could ameliorate prognosis in VAP patients 
(ClinicalTrials.gov Identifier: NCT02440828). Patients 
with a clinically defined VAP were randomly assigned 
to a treatment group receiving twice-daily tobramy-
cin inhalation 300  mg and standard IV AB therapy for 
8  days or to a control group which received twice-daily 
placebo inhalation and standard IV AB treatment for 
8 days. Inclusion and exclusion criteria are described in 
the protocol as supplementary file. Primary outcome was 
treatment failure at day 4, defined as one of the follow-
ing four criteria present at day 4: (1) no improvement 
of the  PaO2/FiO2 ratio, (2) persistence of fever (≥ 38 °C) 
or hypothermia (< 35.5  °C) together with purulent res-
piratory secretions, (3) increase in the pulmonary infil-
trates on chest radiograph of ≥ 50%, and (4) occurrence 
of septic shock or multiple organ dysfunction syndrome, 
defined as three or more organ system failures not pre-
sent on day 1. Secondary outcomes were 30-day mortality 
and number of ventilation free days at day 28. The tar-
get sample size would be 84 patients, which provides 
an 80% power to detect a difference of 32% in cure rate 
between treatments. The study was approved by inde-
pendent and local ethics committee (ethical approval 
number = NL48009.078.14).
The study was terminated prematurely due to insuffi-
cient inclusion. Twenty-six patients were included (treat-
ment, n = 13; control, n = 13) (Table 1). Treatment failure 
was present in four patients (31%) of the treatment group 
and in eight control patients (62%) (p = 0.24, relative 
risk = 0.5). There was no difference in 30-day mortality 
(treatment, n = 4 (31%) vs control, n = 4 (31%). The num-
ber of ventilation free days at day 28 was 18 days [0–21] 
in the treatment group and 17 days [5–22] in the control 
group.
A meta-analysis conducted by Xu et  al. suggests that 
treatment with aerosolized tobramycin resulted in clini-
cal recovery benefits, but this was mostly based on obser-
vational studies [2]. Two recent prospective trials did 
not show a benefit of inhaled AB therapy as adjunctive 
treatment for VAP [3, 4]. The findings of our explorative 
double-blind randomized-controlled trial failed to show 
a beneficial effect of adjunctive tobramycin inhalation 
therapy in the treatment of VAP. However, due to the 
small number of patients, the current study was under-
powered. The relative risk for therapy failure at day 4 in 
the study group compared to the control group is 0.5 
(95% CI 0.19–1.3), meaning that therapy failure occurred 
twice as often in the control group. The next step is to 
investigate whether inhalation antibiotics could be ben-
eficial in certain subgroups, such as an infection with 
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MDR microorganisms, as has also been recommended in 
a recent review [5].
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Table 1 Baseline values and clinical outcomes
a Criteria for treatment failure: 1. No improvement of the arterial  O2 tension to inspired  O2 fraction ratio. 2. Persistence of fever (≥ 38°) of hypothermia (< 35.5°) 
together with purulent respiratory secretions. 3. Increase in the pulmonary infiltrates on chest radiograph of greater than or equal to 50%. 4. Occurrence of septic 
shock or multiple organ dysfunction syndrome defined as three or more organ system failures not present on day 1
b Ventilation-free days at day 28 after inclusion
c Days stayed at ICU after inclusion until discharge
Treatment 
group, n = 13
Control group, n = 13 Risk difference (95% 
confidence interval)
Relative risk (95% 
confidence interval)
p value
Baseline variables
Age, median [IQR] 58 [42–69] 59 [43–66]
Male, n (%) 10 (77%) 7 (54%)
Smoking
 Never 3 (23%) 1 (8%)
 Former 4 (31%) 2 (15%)
 Current 1 (8%) 2 (15%)
 Unknown 5 (39%) 8 (62%)
Apache II score at inclusion (median) 21 [12–24] 14 [13–24]
CPIS score (median) 7 [5–10] 6 [5–9]
Duration of ventilation before VAP (median) 7.4 [2–22] 15.2 [2–63]
Microbiological confirmation, n (%) 10 (77%) 7 (54%)
Outcome values
Therapy failure, n (%) 4 (31%) 8 (62%) 31% (− 6.6 to 58.3%) 0.5 (0.19–1.18) 0.24
Causes of treatment  failurea
 Criteria, no. 1 0 (0%) 2 (15%)
 Criteria, no. 2 1 (8%) 3 (23%)
 Criteria, no. 3 0 (0%) 0 (0%)
 Criteria, no. 4 1 (8%) 0 (0%)
30-day mortality 4 (31%) 4 (31%) 0% (− 32.4 to 32.4%) 1 (0.33–3.06) 1
Ventilation-free days (median)b 18 [0–21] 17 [5–22]
Days in  ICUc 16 [7–35] 13 [8–17]
Adverse events, n (%) 6 (46%) 4 (31%) − 15% (− 46 to 19.9%) 1.5 (0.57–4.13) 0.69
 None 7 (54%) 9 (70%)
 Bronchospasm 1 (8%) 0 (0%)
 Renal disfunction 0 (0%) 1 (8%)
 Other 5 (38%) 3 (23%)
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